2157 — Lepu Biopharma Share News
0.000.00%
Last trade - 00:00- HK$7.06bn
- HK$7.48bn
- CNY934.87m
Hong Kong-listed Keymed Biosciences' gastric cancer drug meets late-stage trial goals
Brief: Lepu Biopharma Reports Positive Top-Line Results From Global Phase III Trial Of CMG901 (AZD0901)
Lepu Biopharma set to jump most in 7 months on FY profit forecast
Brief: Lepu Biopharma Expects FY Net Profit Attributable
Brief: Lepu Biopharma Says Marketing Approval Got In China For Meiyouheng (Becotatug Vedotin Injection)
Brief: Lepu Biopharma Expects Profit Of Not Less Than RMB24 Million For HY
Brief: Lepu Biopharma Enters Licensing Deal With Excalipoint
Brief: Lepu Biopharma To Place Maximum Of 93.8 Million Placing Shares
HK-listed Lepu jumps most in 5 weeks on exclusive deal with ArriVent BioPharma
Brief: Lepu Biopharma Says Exclusive License Agreement For Novel Adc Mrg007
Brief: Arrivent Biopharma Enters Exclusive License With Lepu Biopharma For Mrg007, An Antibody Drug Conjugate
Lepu Biopharma jumps most in 12 weeks on progress of cancer drug application
Brief: Lepu Biopharma Announces Acceptance Of New Drug Application And Priority- Review Granted By Nmpa To- Mrg003
Brief: Lepu Biopharma Co Says MRG003 Granted Breakthrough Therapy Designation By US FDA
China's Lepu Biopharma climbs to 3-week low on discounted share sale
Brief: Lepu Biopharma Announces Placing Of New H Shares Under General Mandate
Brief: Lepu Biopharma Says Fast Track Designation Granted By US FDA To MRG004A
Brief: Lepu Biopharma Says Pu Zhongjie And Sui Ziye Were Re-Elected As Executive Directors Of Second Session Of Board
CEO